Skip to search
Skip to main content
Back to Search
Start Over
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
Authors :
Verstovsek, Srdan Gerds, Aaron T Vannucchi, Alessandro M Al-Ali, Haifa Kathrin Lavie, David Kuykendall, Andrew T Grosicki, Sebastian Iurlo, Alessandra Goh, Yeow Tee Lazaroiu, Mihaela C Egyed, Miklos Fox, Maria Laura McLornan, Donal Perkins, Andrew Yoon, Sung-Soo Gupta, Vikas Kiladjian, Jean-Jacques Granacher, Nikki Lee, Sung-Eun Ocroteala, Luminita Passamonti, Francesco Harrison, Claire N Klencke, Barbara J Ro, Sunhee Donahue, Rafe Kawashima, Jun Mesa, Ruben Abulafia, Adi Shacham Al-Ali, Haifa Kathrin Andreasson, Bjorn Angona, Anna Ayala, Rosa Bang, Soo-Mee Bank, Bruce Barraco, Fiorenza Beggiato, Eloise Benghiat, Fleur Samantha Bonifacio, MassimiliaNo Bories, Claire Borsaru, Gabriela Brabrand, Mette Braester, Andrei Broliden, Andes Buxhofer-Ausch, Veronika Cambier, Nathalie Caramella, Marianna Carpentier, Benjamin Cascavilla, Nicola Castellano, Maria Giraldo Chang, Hung Chen, Chih-Cheng Cheong, June-Won Choi, Yunsuk Choi, Philip Corsetti, Maria Teresa Cuadrado, Isabel Montero Cunningham, Julia Damaj, Gandhi Laurent De Stefano, Valerio Delage, Robert Delgado, Regina Garcĺa Diaz, Jose Miguel Torregrosa Dombi, Péter Dubruille, Viviane Egyed, Miklós El Fassi, Daniel Elinder-Camburn, Anna Elli, Elena Maria Ellis, Martin Fava, Carmen Fazal, Salman Fleischman, Angela Foltz, Lynda Fox, Laura Gabrail, Nashat Garcĺa-Gutiérrez, Jose Valentĺn Gerds, Aaron Girault, Stephane Gisslinger, Heinz Gluvacov, Alexandru Goh, Yeow Tee Göthert, Joachim Granacher, Nikki Grosicki, Sebastian Gupta, Vikas Hadjiev (Hadzhiev), Evgeni (Evgueniy) Hafraoui, Kaoutar Hamed, Aryan Harrison, Claire Hasselbalch, Hans Hauser, Hanns Heaney, Mark Hebart, Holger Hernandez Rivas, Jesus Maria Higuero Saavedra, Victor Hillis, Christopher Hou, Hsin-An How, Jonathan Huang, Daniel Hus, Marek Illés, Arpad Isidori, Alessandro Iurlo, Alessandra Ivanov, Vadim Johansson, Peter Jung, Chul Won Kiladjian, Jean-Jacques Kirgner, Ilya Koren-Michowitz, Maya Koschmieder, Steffen Kosztolanyi, Szabolcs Ors Kreiniz, Natalia Kuykendall, Andrew Lambert, Jonathan Laribi, Kamel Lascaux, Axelle Lavie, Noa Lavie, David Lazaroiu, Mihaela Leahy, Michael Lech-Maranda, Ewa Lee, Sung-Eun Lee, Won Sik Legrand, Ollivier Lemoli, Roberto Liang, James Lim, Sung-Nam Loschi, Michael Lucchesi, Alessandro Macarie, Ioan Marolleau, Jean-Pierre Martelli, Maurizio Mayer, Jiri McCloskey, James McDermott, Christopher McLornan, Donal McMahon, Brandon Mehta, Priyanka Mesa, Ruben Mikala, Gábor Milojkovic, Dragana Mineur, Philippe Mishchenko, Elena Moon, Joon Ho Nagy, Zsolt Narayanan, Srinivasan O'Connell, Casey Ocroteala, Luminita Oh, Stephen Ojeda-Uribe, Mario Ong, Kiat Hoe Otegbeye, Folashade Palmer, Jeanne Pane, Fabrizio Passamonti, Francesco Patriarca, Andrea Perkins, Andrew Pietrantuono, Giuseppe Plander, Mark Platzbecker, Uwe Prasad, Ritam Prejzner, Witold Rachow, Tobias Radinoff, Atanas Rejtő, László Rinaldi, Ciro Robak, Tadeusz Rodriguez, Maria Angeles Fernandez Ronson, Aaron Ross, David Sacha, Tomasz Sadjadian, Parvis Salar, Antonio Santillana, Guillermo Sanz Scheid, Christof Schmidt, Aline Severinsen, Marianne Tang Stoeva, Vera Szwedyk, Paweł Tiribelli, Mario Trautmann-Grill, Karolin Trottier, Amy Tzvetkov, Nikolay van Droogenbroeck, Janusz Vannucchi, Alessandro Verstovsek, Srdan Vianelli, Nicola von Bubnoff, Nikolas Wolf, Dominik Woszczyk, Dariusz Woźny, Tomasz Wróbel, Tomasz Xicoy, Blanca Yeh, Su-Peng Yoon, Sung-Soo
Source :
The Lancet; January 2023, Vol. 401 Issue: 10373 p269-280, 12p
Publication Year :
2023
Abstract
Janus kinase (JAK) inhibitors approved for myelofibrosis provide spleen and symptom improvements but do not meaningfully improve anaemia. Momelotinib, a first-in-class inhibitor of activin A receptor type 1 as well as JAK1 and JAK2, has shown symptom, spleen, and anaemia benefits in myelofibrosis. We aimed to confirm the differentiated clinical benefits of momelotinib versus the active comparator danazol in JAK-inhibitor-exposed, symptomatic patients with anaemia and intermediate-risk or high-risk myelofibrosis.
Details
Language :
English
ISSN :
01406736 and 1474547X
Volume :
401
Issue :
10373
Database :
Supplemental Index
Journal :
The Lancet
Publication Type :
Periodical
Accession number :
ejs62045289
Full Text :
https://doi.org/10.1016/S0140-6736(22)02036-0